Clinical trials: Cancer (Advanced Stage)
Solid Tumors
Phase I Comparative Bioavailability Study
The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients
- Trial name
- NCT00777582
- Testing
- AZD2281
- Where
- 10 sites in Australia, Belgium and 2 more
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors
PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific…
- Trial name
- mRNA-LNP (NCT07587879)
- Testing
- mRNA-LNP
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IntraAb, Inc.
Pancreas Cancer, Biliary Tract Cancer
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or…
- Conditions
- Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
- Trial name
- NCT05220046
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Nebraska
Lung Cancer, Non-Small Cell Lung Cancer
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.
- Trial name
- NCT00354562
- Testing
- ABT-751, Docetaxel
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Abbott
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of muscadine grape skin extract (MGE) in treating patients with malignancy (tumor or cancer) that has spread to other parts of the body or cannot be removed by…
- Conditions
- Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT02583269
- Testing
- Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive.
- Trial name
- NCT04165083
- Testing
- Pembrolizumab, MK-4830, MK-0482
- Where
- 39 sites in United States, Hungary and 5 more
- Volunteers
- 102 people
- Sponsor
- Merck Sharp & Dohme LLC
Safety, Tolerability
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of…
- Conditions
- Safety, Tolerability, Efficacy
- Trial name
- NCT06243354
- Testing
- Test product: HYP-2090PTSA
- Where
- 6 sites in China
- Volunteers
- 257 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Prostate Cancer
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced or metastatic…
- Trial name
- NCT02867020
- Testing
- Apalutamide, Abiraterone, ADT
- Where
- 14 sites in Brazil
- Volunteers
- 128 people
- Sponsor
- Latin American Cooperative Oncology Group
Advanced Malignant Solid Tumors
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs…
- Trial name
- NCT00958724
- Testing
- Neratinib, Vinorelbine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Puma Biotechnology, Inc.
NSCLC Stage IV
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.
- Trial name
- NCT04106180
- Testing
- GM-CSF, Sintilimab, SBRT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma. type of study: clinical trial
- Trial name
- NCT06165380
- Testing
- Cardenilimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Li Zhang
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.
- Trial name
- NCT00929162
- Testing
- ZD4054 Zibotentan, Paclitaxel, Carboplatin
- Where
- 20 sites in Germany, Italy
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
This is a Phase I/Ib, open-label, multicenter, dose-escalation trial of paclitaxel in combination with defactinib (VS-6063), a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.
- Trial name
- NCT01778803
- Testing
- defactinib, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Verastem, Inc.
Non-Small-Cell Lung Cancer Stage IV
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC) with previously failed after…
- Trial name
- NCT04238169
- Testing
- Bevacizumab, Toripalimab, SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinqiao Hospital of Chongqing
Chordoma
A Study of ERAS-601 in People With Chordoma
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
- Trial name
- NCT06957327
- Testing
- ERAS-601
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms, Chemotherapy
XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
Colorectal cancer will be resistant to Chemotherapy drugs after treated for a period of time .In the past, the classical treatment regiment was to change other drug after tumor progressed.
- Trial name
- NCT03511170
- Testing
- XELIRI, XELOX
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Harbin Medical University